Nishimoto, N., Yoshizaki, K., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Hashimoto, J., Azuma, J. and Kishimoto, T. (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis & Rheumatism, 50, 1761-1769. doi:10.1002/art.20303

has been cited by the following article:

• TITLE: Remission of arthritis but persistent cutaneous lesions following tocilizumab treatment in a RA-patient suffering from concomitant psoriasis

  AUTHORS: Wolfgang Hartung, Boris Ehrenstein, Rotraud Wallisch, Martin Fleck

  KEYWORDS: Tocilizumab; Rheumatoid Arthritis; Psoriasis; Treatment

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.2 No.1, March 25, 2013

  ABSTRACT: Modulation of the interleukin-6 pathway with tocilizumab has been demonstrated to be highly effective in substantial numbers of patients suffering from rheumatoid arthritis (RA), and juvenile idiopathic arthritis. A pivotal role of the IL-6 pathway has been also established in other autoimmune conditions including psoriasis and psoriatic arthritis, becoming attractive targets for therapeutic IL-6 inhibition. Here, we describe the first case of tocilizumab treatment in a RA-patient suffering from concomitant severe psoriasis, who achieved remission of RA, whereas no improvement of psoriatic lesions could be observed.